HomeBUSINESS
BUSINESS

Halaven/Keytruda Combo Delivers ORR of 26.4% in Triple-Negative Breast Cancer: Interim Data
(Dec.11.2017)

Eisai said on December 8 that a combination of its anticancer drug Halaven (eribulin) and US Merck’s PD-1 inhibitor Keytruda (pembrolizumab) achieved an objective response rate (ORR) of 26.4% in metastatic triple-negative breast cancer, according to interim analysis data from a US PIb/II study ...
(LOG IN FOR FULL STORY)